Clinical trials: Chemotherapeutic Agent Toxicity
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Dermatitis, Adverse Drug Reaction
MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY
Capecitabine is a drug that produces dermatologic toxicity frequently (palmoplantar erythrodysesthesia, rash , alopecia , erythema , dryness, pruritus, hyperpigmentation , rash, peeling , dermatitis , abnormal pigmentation, and…
- Trial name
- B-DUOL (NCT02036957)
- Testing
- BALM ARM
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Basque Health Service
Chemotherapeutic Agent Toxicity, Infection
Using Whole-Person-Care Guide in Patients Receiving Care for Cancer or Complications From Cancer Treatment
RATIONALE: Gathering information about patients with cancer and cancer-related conditions may help doctors learn more about a patient's needs and help doctors plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Infection, Malnutrition, Musculoskeletal Complications
- Trial name
- NCT00608738
- Testing
- informational intervention, medical chart review, questionnaire administration
- Volunteers
- 750 people
- Sponsor
- Northwestern University
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in…
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
- Trial name
- NCT00748215
- Testing
- calcium aluminosilicate anti-diarrheal
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
This phase I trial is studying the side effects and best dose of cisplatin given together with paclitaxel in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or…
- Conditions
- Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma, Fallopian Tube Carcinoma, Gastrointestinal Complication
- Trial name
- NCT00814086
- Testing
- Paclitaxel, Cisplatin
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Cardiotoxicity, Chemotherapeutic Toxicity
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome.
- Trial name
- NCT00292526
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 114 people
- Sponsor
- European Institute of Oncology
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Aerobic Exercise in Patients Receiving Chemotherapy for Cancer
RATIONALE: Aerobic exercise may help prevent side effects caused by chemotherapy and help improve heart health. PURPOSE: This randomized clinical trial is studying the side effects of aerobic exercise and to see how well it works…
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00728429
- Testing
- exercise intervention
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Chemotherapeutic Agent Toxicity, Neutropenia
G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy
RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00770172
- Testing
- filgrastim
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Centre Francois Baclesse
Nutrition Aspect of Cancer, Sarcopenia
Malnutrition and Sarcopenia Screening in Chemotherapy Patients
The study will include approximately 150 adult outpatients diagnosed with solid tumors who are currently receiving chemotherapy.
- Conditions
- Nutrition Aspect of Cancer, Sarcopenia, Chemotherapeutic Agent Toxicity
- Trial name
- NCT07163286
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Çanakkale Onsekiz Mart University
Cancer, Chemotherapeutic Agent Toxicity
Telemonitoring Platforms and Chemotherapy-Associated Toxicity
The primary objective of this trial is to evaluate the impact of a telemonitoring platform on patient satisfaction with care amongst adult cancer patients receiving chemotherapy.
- Trial name
- DETECT (NCT06077123)
- Testing
- Contigo Application
- Where
- 2 sites in Chile
- Volunteers
- 80 people
- Sponsor
- Universidad Nacional Andres Bello
Urologic Neoplasms, Urogenital Neoplasms
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment…
- Conditions
- Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms
- Trial name
- TURANDORELA (NCT06237920)
- Testing
- Nivolumab, Relatlimab
- Where
- 9 sites in Netherlands
- Volunteers
- 90 people
- Sponsor
- The Netherlands Cancer Institute
Chemotherapeutic Agent Toxicity, Sarcoma
CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With Ifosfamide
RATIONALE: Studying the genes expressed in samples of blood from young patients with cancer treated with ifosfamide may help doctors identify risk factors for kidney damage.
- Conditions
- Chemotherapeutic Agent Toxicity, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00514345
- Testing
- gene expression analysis, polymorphism analysis, management of therapy complications
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 300 people
- Sponsor
- Children's Cancer and Leukaemia Group
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Cancer, Symptoms and Signs
Mobile App for Symptoms Monitoring in Cancer Patients: a Pilot Study
With the growing number of cancer survivors, challenges to deal with comorbidities and impacted quality of life of cancer survivors by the disease and treatments also surge.
- Conditions
- Cancer, Symptoms and Signs, Quality of Life, Chemotherapeutic Agent Toxicity
- Trial name
- NCT04572282
- Testing
- Mentora app
- Volunteers
- 30 people
- Sponsor
- Associacao de Investigacao de Cuidados de Suporte em Oncologia
Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer
GALENOS 1 in Head and Neck, Lung, and Rectal Cancer Patients
GALENOS 1 is a prospective observational study designed to explore longitudinal changes in nutritional status and body composition in patients with head and neck squamous cell carcinoma, locally advanced rectal cancer, and lung…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer, Lung Cancer
- Trial name
- GALENOS 1 (NCT07511413)
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Cardiotoxicity, Heart Failure
MyoStrain CMR for the Detection of Cardiotoxicity
The Prefect Pilot Study evaluates the use of the EC approved MyoStrain SENC CMR Imaging System to detect cardiotoxicity from drugs used to treat cancer (e.g. Breast Cancer and Lymphomas).
- Conditions
- Cardiotoxicity, Heart Failure, Chemotherapeutic Toxicity
- Trial name
- Prefect (NCT03543228)
- Testing
- MyoStrain
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Myocardial Solutions
Chemotherapeutic Agent Toxicity, Colorectal Cancer
Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin for cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to neurotoxicity.
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neurotoxicity
- Trial name
- NCT00884767
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Institut Cancerologie de l'Ouest
Chemotherapeutic Agent Toxicity, Mucositis
Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy
This randomized phase II trial is studying how well selenomethionine (SLM) works in reducing mucositis in patients with locally advanced head and neck cancer who are receiving cisplatin and radiation therapy.
- Conditions
- Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01682031
- Testing
- selenomethionine, cisplatin, radiation therapy
- Where
- 2 sites in United States, New Zealand
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute